Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
17 Jun 2024
17 Jun 2024
Historique:
accepted:
26
05
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
17
6
2024
Statut:
aheadofprint
Résumé
CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with RAS wild type (wt) metastatic colorectal cancer (mCRC). We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with CRC liver metastasis (LM). Patients with LM that could be measured by enhanced contrast phase computed tomography (CT) imaging at baseline and at first response evaluation were included. Multiple texture parameters were extracted with the LifeX Software. Delta-texture (D-TA) variations were calculated by comparing data at baseline and after treatment. Overall, 55/77 patients (71%) had LM; 39 met the inclusion criteria for the current analysis. The D-TA parameters that significantly correlated at univariate analysis with median progression-free survival (mPFS) were Entropy Reduction in the D-TA parameter Homogeneity
Sections du résumé
BACKGROUND
BACKGROUND
CAVE is a single arm, Phase 2 trial, that demonstrated anti-tumor activity of cetuximab rechallenge plus avelumab in patients with RAS wild type (wt) metastatic colorectal cancer (mCRC).
OBJECTIVE
OBJECTIVE
We conducted a post hoc analysis to identify potential radiomic biomarkers for patients with CRC liver metastasis (LM).
PATIENTS AND METHODS
METHODS
Patients with LM that could be measured by enhanced contrast phase computed tomography (CT) imaging at baseline and at first response evaluation were included. Multiple texture parameters were extracted with the LifeX Software. Delta-texture (D-TA) variations were calculated by comparing data at baseline and after treatment.
RESULTS
RESULTS
Overall, 55/77 patients (71%) had LM; 39 met the inclusion criteria for the current analysis. The D-TA parameters that significantly correlated at univariate analysis with median progression-free survival (mPFS) were Entropy
CONCLUSION
CONCLUSIONS
Reduction in the D-TA parameter Homogeneity
Identifiants
pubmed: 38886336
doi: 10.1007/s40261-024-01372-0
pii: 10.1007/s40261-024-01372-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Regione Campania
ID : Cup 21C17000030007
Organisme : Merck Healthcare KGaA
ID : Grant
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72(4):372–401. https://doi.org/10.3322/caac.21728 .
doi: 10.3322/caac.21728
pubmed: 35472088
Cremolini C, Rossini D, Dell’Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343–50. https://doi.org/10.1001/jamaoncol.2018.5080 .
doi: 10.1001/jamaoncol.2018.5080
pubmed: 30476968
Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the Phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612–8. https://doi.org/10.1038/s41591-022-01886-0 .
doi: 10.1038/s41591-022-01886-0
pubmed: 35915157
pmcid: 9386661
Napolitano S, De Falco V, Martini G, et al. Panitumumab plus trifluridine-tipiracil as anti-epidermal growth factor receptor rechallenge therapy for refractory RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial [published correction appears in JAMA Oncol. 2024;10(4):541. https://doi.org/10.1001/jamaoncol.2024.0068 ]. JAMA Oncol. 2023;9(7):966–70. https://doi.org/10.1001/jamaoncol.2023.0655 .
Napolitano S, Ciardiello D, De Falco V, et al. Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: overall survival and subgroup analysis of the randomized phase II VELO trial [published online ahead of print, 2023 Jun 30]. Int J Cancer. 2023. https://doi.org/10.1002/ijc.34632.10.1002/ijc.34632 .
doi: 10.1002/ijc.34632.10.1002/ijc.34632
pubmed: 37391938
Parseghian CM, Loree JM, Morris VK, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243–9. https://doi.org/10.1093/annonc/mdy509 .
doi: 10.1093/annonc/mdy509
pubmed: 30462160
Ciardiello D, Mauri G, Sartore-Bianchi A, et al. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: a systematic review. Cancer Treat Rev. 2024;124: 102683. https://doi.org/10.1016/j.ctrv.2024.102683 .
doi: 10.1016/j.ctrv.2024.102683
pubmed: 38237253
Martinelli E, Martini G, Famiglietti V, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021;7(10):1529–35. https://doi.org/10.1001/jamaoncol.2021.2915 .
doi: 10.1001/jamaoncol.2021.2915
pubmed: 34382998
Ciardiello D, Famiglietti V, Napolitano S, et al. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. Clin Colorectal Cancer. 2022;21(2):141–8. https://doi.org/10.1016/j.clcc.2022.01.005 .
doi: 10.1016/j.clcc.2022.01.005
pubmed: 35101346
Mayerhoefer ME, Materka A, Langs G, et al. Introduction to radiomics. J Nucl Med. 2020;61(4):488–95. https://doi.org/10.2967/jnumed.118.222893 .
doi: 10.2967/jnumed.118.222893
pubmed: 32060219
pmcid: 9374044
Arimura H, Soufi M, Ninomiya K, Kamezawa H, Yamada M. Potentials of radiomics for cancer diagnosis and treatment in comparison with computer-aided diagnosis. Radiol Phys Technol. 2018;11(4):365–74. https://doi.org/10.1007/s12194-018-0486-x .
doi: 10.1007/s12194-018-0486-x
pubmed: 30374837
Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–62. https://doi.org/10.1038/nrclinonc.2017.141 .
doi: 10.1038/nrclinonc.2017.141
pubmed: 28975929
Eloyan A, Yue MS, Khachatryan D. Tumor heterogeneity estimation for radiomics in cancer. Stat Med. 2020;39(30):4704–23. https://doi.org/10.1002/sim.8749 .
doi: 10.1002/sim.8749
pubmed: 32964647
pmcid: 8244619
Badic B, Tixier F, Cheze Le Rest C, Hatt M, Visvikis D. Radiogenomics in colorectal cancer. Cancers (Basel). 2021;13(5):973. https://doi.org/10.3390/cancers13050973 . (Published 2021 Feb 26).
doi: 10.3390/cancers13050973
pubmed: 33652647
pmcid: 7956421
Nardone V, Reginelli A, Guida C, et al. Delta-radiomics increases multicentre reproducibility: a phantom study. Med Oncol. 2020;37(5):38. https://doi.org/10.1007/s12032-020-01359-9 . (Published 2020 Mar 31).
doi: 10.1007/s12032-020-01359-9
pubmed: 32236847
Nioche C, Orlhac F, Boughdad S, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78(16):4786–9. https://doi.org/10.1158/0008-5472.CAN-18-0125 .
doi: 10.1158/0008-5472.CAN-18-0125
pubmed: 29959149
Nardone V, Tini P, Pastina P, et al. Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. Oncol Lett. 2020;19(2):1559–66. https://doi.org/10.3892/ol.2019.11220 .
doi: 10.3892/ol.2019.11220
pubmed: 31966081
Bullock AJ, Fakih MG, Gordon MS, et al. Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer. Ann Oncol. 2023;34(suppl 1):S178–9.
doi: 10.1016/j.annonc.2023.04.014
Ciardiello D, Martinelli E, Troiani T, et al. Anti-EGFR rechallenge in patients with refractory ctDNA RAS/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial [published correction appears in JAMA Netw Open. 2024 May 1;7(5):e2418437]. JAMA Netw Open. 2024;7(4):e245635. https://doi.org/10.1001/jamanetworkopen.2024.5635 . (Published 2024 Apr 1).
doi: 10.1001/jamanetworkopen.2024.5635
pubmed: 38592721
pmcid: 11004834
Ravanelli M, Agazzi GM, Tononcelli E, et al. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy. Radiol Med. 2019;124(9):877–86. https://doi.org/10.1007/s11547-019-01046-4 .
doi: 10.1007/s11547-019-01046-4
pubmed: 31172448
Granata V, Fusco R, Setola SV, et al. CT-based radiomics analysis to predict histopathological outcomes following liver resection in colorectal liver metastases. Cancers (Basel). 2022;14(7):1648. https://doi.org/10.3390/cancers14071648 . (Published 2022 Mar 24).
doi: 10.3390/cancers14071648
pubmed: 35406419
pmcid: 8996874
Andersen IR, Thorup K, Andersen MB, et al. Texture in the monitoring of regorafenib therapy in patients with colorectal liver metastases. Acta Radiol. 2019;60(9):1084–93. https://doi.org/10.1177/0284185118817940 .
doi: 10.1177/0284185118817940
pubmed: 30612433
Giannini V, Rosati S, Defeudis A, et al. Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy. Int J Cancer. 2020;147(11):3215–23. https://doi.org/10.1002/ijc.33271 .
doi: 10.1002/ijc.33271
pubmed: 32875550
Lubner MG, Stabo N, Lubner SJ, et al. CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes. Abdom Imaging. 2015;40(7):2331–7. https://doi.org/10.1007/s00261-015-0438-4 .
doi: 10.1007/s00261-015-0438-4
pubmed: 25968046
Ahn SJ, Kim JH, Park SJ, Han JK. Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis. Eur J Radiol. 2016;85(10):1867–74. https://doi.org/10.1016/j.ejrad.2016.08.014 .
doi: 10.1016/j.ejrad.2016.08.014
pubmed: 27666629
Napolitano S, Martini G, Ciardiello D, et al. CAVE-2 (Cetuximab-AVElumab) mCRC: a phase II randomized clinical study of the combination of avelumab plus cetuximab as a rechallenge strategy in pre-treated RAS/BRAF wild-type mCRC patients. Front Oncol. 2022;12:940523. https://doi.org/10.3389/fonc.2022.940523 . (Published 2022 Jun 27).
doi: 10.3389/fonc.2022.940523
pubmed: 35832541
pmcid: 9272566